These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: The euphoria of hypomethylating agents in MDS and AML: is it justified?
    Author: Sekeres MA.
    Journal: Best Pract Res Clin Haematol; 2013 Sep; 26(3):275-8. PubMed ID: 24309530.
    Abstract:
    While it is logical to use hypomethylating agents to treat patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), trial results with azacitidine and decitabine have been inconsistent. Azacitidine confers a survival benefit in higher-risk MDS patients, while decitabine does not. Neither agent has demonstrated a survival advantage in older AML patients in prospective studies. Reasons for this are explored here along with a recommendation to reconsider clinical trial design endpoints.
    [Abstract] [Full Text] [Related] [New Search]